Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist
about
A mathematical analysis of SELEXMolecular beacons with a homo-DNA stem: improving target selectivityMIPs and Aptamers for Recognition of Proteins in Biomimetic Sensing.Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery SystemsNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingIn vitro selection using a dual RNA library that allows primerless selectionCharacterization of long RNA-cleaving deoxyribozymes with short catalytic cores: the effect of excess sequence elements on the outcome of in vitro selection.Combining SELEX and the yeast three-hybrid system for in vivo selection and classification of RNA aptamersThe shorter the better: reducing fixed primer regions of oligonucleotide libraries for aptamer selection.Aptamers and the next generation of diagnostic reagents.Aptamer-targeted cell-specific RNA interferenceStrategies for the discovery of therapeutic aptamers.Recent developments in protein and cell-targeted aptamer selection and applicationsMultiplexed microcolumn-based process for efficient selection of RNA aptamers.An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.High-throughput binding characterization of RNA aptamer selections using a microplate-based multiplex microcolumn deviceLocal neutral networks help maintain inaccurately replicating ribozymesAptamers as a novel tool for diagnostics and therapy.In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategiesThe chemical biology of aptamers.Exploring the role of chirality in nucleic acid recognition.Nucleic acid and peptide aptamers: fundamentals and bioanalytical aspects.Characterisation of aptamers for therapeutic studies.Aptamers: problems, solutions and prospects.Aptamer and its potential applications for food safety.In vitro selection of RNA aptamers directed against protein E: a Haemophilus influenzae adhesin.Nucleic acid aptamers in cancer research, diagnosis and therapy.Using aptamers as capture reagents in bead-based assay systems for diagnostics and hit identification.Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide.Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.Aptamer and its applications in neurodegenerative diseases.Advances in the development of aptamer drug conjugates for targeted drug delivery.Optimization of ultrasound contrast agents with computational models to improve selection of ligands and binding strength.Locked nucleic acid and aptamers.Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.Aptamers and Their Significant Role in Cancer Therapy and Diagnosis.
P2860
Q24643926-3B47F7DA-4A23-422C-BF71-74240252F44AQ24798325-3FFA735E-8CE2-4C10-9E14-BA240B2CF301Q26738688-9C50FA00-7145-4198-A55D-1236E61AA185Q26782485-9D0831D1-8104-43C1-8CDB-6FAF9E4D3796Q26825644-50BF45DA-CE57-43A7-8813-81EF2889E7D5Q29036552-F627F9B1-02AF-4AE9-B4DC-7D19C32C42F2Q33242772-721A1833-602A-4E3C-A808-CC4C9EB3024DQ33272405-5BC936A6-DE5E-4EF8-9620-49F8448227F6Q33433379-8CBB8E28-539C-46B1-A000-30C37A2B6E82Q33615065-572A3BA6-E056-43B4-9CA8-DA176D48DAD0Q33717239-97DA43A8-DC15-4FB3-894F-EADAC34DEBB7Q33831862-835F25A1-2D05-46F3-A620-471A4A4A4096Q33908491-06DAF4DC-8A3B-40B4-9278-43F9AF6BD38EQ34582183-BA5C5E59-747C-4020-AB6B-AC3C3703FAC7Q34597041-2F8C6531-9507-4EAF-B140-DE2F853A0A2CQ35098386-47FC3C78-047E-4E30-B1DD-050668FF7184Q35316425-55AEAB3A-8218-4C9D-A404-66365F9E3885Q35552275-F9CE09AA-2941-453C-99B3-FADA26C10C3DQ36156320-921AE33A-75FC-4906-9A7A-3D9E270CC29BQ37423243-34E6FF68-3947-4F1A-8FAA-0CCCAA3DC1D5Q37853120-22BE42FB-E87D-44B2-9F1E-78AA17593701Q37972851-FCABFD81-02D7-4851-AFCA-B55DBD5FB6B8Q38089865-B3107625-5409-4161-BE4E-0448F9F7EF63Q38181121-43E71F3E-09B7-43C2-B6BC-137CB7B5801EQ38192082-70BC0E69-CF05-4605-898C-FFB5B6E3009FQ38308093-930A46DF-98AD-403E-AE70-3915C5789B84Q38308357-055CE296-A193-4348-ABAE-6ADA9BC52840Q38310154-116AD9C1-280A-4924-8A23-08FD1603D7B5Q38313986-43CC5FC2-3F67-4E34-8C36-225EE1C76DF1Q38339945-DA8998AB-ED21-41DA-B66E-AF5CB82EF96FQ38937721-090585E9-5A64-48B3-9DFC-F7979E3118F1Q38995729-D437C61E-1705-497A-AAB1-689050623D3DQ39411412-1E1666FF-834B-41DA-896C-FDAEF7EA5244Q42357589-F8CEDE59-6627-4D8A-8C24-F592BCFAEBD8Q47104247-889F5730-4C53-4717-9C78-10CE011E198DQ54457076-2A6C19A4-68C3-4936-9D3A-022B6276EEE6
P2860
Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Development of an automated in ...... ostable substance P antagonist
@ast
Development of an automated in ...... ostable substance P antagonist
@en
Development of an automated in ...... ostable substance P antagonist
@nl
type
label
Development of an automated in ...... ostable substance P antagonist
@ast
Development of an automated in ...... ostable substance P antagonist
@en
Development of an automated in ...... ostable substance P antagonist
@nl
prefLabel
Development of an automated in ...... ostable substance P antagonist
@ast
Development of an automated in ...... ostable substance P antagonist
@en
Development of an automated in ...... ostable substance P antagonist
@nl
P2093
P2860
P3181
P356
P1476
Development of an automated in ...... ostable substance P antagonist
@en
P2093
Christian Maasch
Dirk Eulberg
Klaus Buchner
Sven Klussmann
P2860
P3181
P356
10.1093/NAR/GNI044
P407
P577
2005-01-01T00:00:00Z